IT201700066486A1 - Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche - Google Patents

Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche

Info

Publication number
IT201700066486A1
IT201700066486A1 IT102017000066486A IT201700066486A IT201700066486A1 IT 201700066486 A1 IT201700066486 A1 IT 201700066486A1 IT 102017000066486 A IT102017000066486 A IT 102017000066486A IT 201700066486 A IT201700066486 A IT 201700066486A IT 201700066486 A1 IT201700066486 A1 IT 201700066486A1
Authority
IT
Italy
Prior art keywords
ophthalmological
treatment
neurodegenerative diseases
blood serum
serum
Prior art date
Application number
IT102017000066486A
Other languages
English (en)
Inventor
Emilio C Campos
Piera Versura
Marina Buzzi
Silvia Bisti
Claudio Velati
Original Assignee
Azienda Ospedaliero Univ Policlinico S Orsola Malpighi Bologn A
Univ Bologna Alma Mater Studiorum
Univ Degli Studi Dellaquila
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azienda Ospedaliero Univ Policlinico S Orsola Malpighi Bologn A, Univ Bologna Alma Mater Studiorum, Univ Degli Studi Dellaquila filed Critical Azienda Ospedaliero Univ Policlinico S Orsola Malpighi Bologn A
Priority to IT102017000066486A priority Critical patent/IT201700066486A1/it
Priority to CN201880053409.6A priority patent/CN110996973A/zh
Priority to EP23156135.8A priority patent/EP4201414A1/en
Priority to ES18737995T priority patent/ES2947577T3/es
Priority to CA3066980A priority patent/CA3066980A1/en
Priority to US16/622,481 priority patent/US20200138860A1/en
Priority to PCT/IB2018/054410 priority patent/WO2018229718A1/en
Priority to JP2020519195A priority patent/JP2020523416A/ja
Priority to EP18737995.3A priority patent/EP3638259B1/en
Publication of IT201700066486A1 publication Critical patent/IT201700066486A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
IT102017000066486A 2017-06-15 2017-06-15 Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche IT201700066486A1 (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IT102017000066486A IT201700066486A1 (it) 2017-06-15 2017-06-15 Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche
CN201880053409.6A CN110996973A (zh) 2017-06-15 2018-06-15 用于治疗神经退行性眼科病变的血清
EP23156135.8A EP4201414A1 (en) 2017-06-15 2018-06-15 Blood serum for use in the treatment of neurodegenerative ophthalmologic pathologies
ES18737995T ES2947577T3 (es) 2017-06-15 2018-06-15 Uso de suero sanguíneo en el tratamiento de patologías oftalmológicas neurodegenerativas
CA3066980A CA3066980A1 (en) 2017-06-15 2018-06-15 Blood serum for use in the treatment of neurodegenerative ophthalmological pathologies
US16/622,481 US20200138860A1 (en) 2017-06-15 2018-06-15 Blood serum for use in the treatment of neurodegenerative ophthalmological pathologies
PCT/IB2018/054410 WO2018229718A1 (en) 2017-06-15 2018-06-15 Blood serum for use in the treatment of neurodegenerative ophthalmological pathologies
JP2020519195A JP2020523416A (ja) 2017-06-15 2018-06-15 神経変性眼科学的病状の治療に使用する血清
EP18737995.3A EP3638259B1 (en) 2017-06-15 2018-06-15 Blood serum for use in the treatment of neurodegenerative ophthalmological pathologies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102017000066486A IT201700066486A1 (it) 2017-06-15 2017-06-15 Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche

Publications (1)

Publication Number Publication Date
IT201700066486A1 true IT201700066486A1 (it) 2018-12-15

Family

ID=60138825

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102017000066486A IT201700066486A1 (it) 2017-06-15 2017-06-15 Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche

Country Status (8)

Country Link
US (1) US20200138860A1 (it)
EP (2) EP4201414A1 (it)
JP (1) JP2020523416A (it)
CN (1) CN110996973A (it)
CA (1) CA3066980A1 (it)
ES (1) ES2947577T3 (it)
IT (1) IT201700066486A1 (it)
WO (1) WO2018229718A1 (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230210895A1 (en) 2020-08-03 2023-07-06 Sereye Gmbh Composition for treating damaged epithelial surfaces and method of producing same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210185A (en) * 1988-03-18 1993-05-11 Fidia S.P.A. Human nerve growth factor
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100514277B1 (ko) * 1996-09-13 2005-09-13 유겐가이샤 사이센딴이가꾸겡꾸쇼 신경 영양 인자의 안과용 조성물, 시신경 기능 장애 치료제 및 시신경 기능 장애 치료 방법
US20020102581A1 (en) * 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
EP1507552A2 (en) * 2002-05-28 2005-02-23 Novocell, Inc. Methods, compositions, and growth and differentiation factors for insulin-producing cells
TWI486171B (zh) * 2009-05-04 2015-06-01 亞培研究公司 具有增進之體內穩定性之抗神經生長因子（ｎｇｆ）抗體

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210185A (en) * 1988-03-18 1993-05-11 Fidia S.P.A. Human nerve growth factor
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AJAMI A ET AL: "Changes in serum levels of brain derived neurotrophic factor and nerve growth factor-beta in schizophrenic patients before and after treatment.", SCANDINAVIAN JOURNAL OF IMMUNOLOGY JUL 2014, vol. 80, no. 1, July 2014 (2014-07-01), pages 36 - 42, XP002777952, ISSN: 1365-3083 *
KOHSAKA S ET AL: "Increased activity of ornithine decarboxylase in goldfish following optic nerve crush", DEVELOPMENTAL BRAIN RESEARCH, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1, no. 3, 1 June 1981 (1981-06-01), pages 391 - 401, XP024320502, ISSN: 0165-3806, [retrieved on 19810601], DOI: 10.1016/0165-3806(81)90076-6 *
LAKSHMANAN J: "Beta-nerve growth factor measurements in mouse serum.", JOURNAL OF NEUROCHEMISTRY MAR 1986, vol. 46, no. 3, March 1986 (1986-03-01), pages 882 - 891, XP002777951, ISSN: 0022-3042 *
YIP H K ET AL: "Effect of nerve growth factor on regeneration of goldfish optic axons", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 238, no. 2, 29 April 1982 (1982-04-29), pages 329 - 339, XP024259227, ISSN: 0006-8993, [retrieved on 19820429], DOI: 10.1016/0006-8993(82)90108-1 *

Also Published As

Publication number Publication date
EP4201414A1 (en) 2023-06-28
WO2018229718A1 (en) 2018-12-20
EP3638259A1 (en) 2020-04-22
CA3066980A1 (en) 2018-12-20
JP2020523416A (ja) 2020-08-06
ES2947577T3 (es) 2023-08-11
CN110996973A (zh) 2020-04-10
US20200138860A1 (en) 2020-05-07
EP3638259B1 (en) 2023-02-15

Similar Documents

Publication Publication Date Title
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
GB201517215D0 (en) Use of cannabinoids in the treatment of inflammatory skin diseases
EP3122878A4 (en) Mrna therapy for the treatment of ocular diseases
PT3377637T (pt) Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
WO2014176128A3 (en) Compositions and methods for the therapy and diagnosis of influenza
DK3668513T3 (da) Pyruvatkinase-aktiveringsmidler til anvendelse til behandling af blodsygdomme
HK1246669A1 (zh) 人血清白蛋白低分子量組分在疾病治療中的應用
IL239629B (en) History of benzylideneguanidine and therapeutic use for the treatment of diseases resulting from misfolding of proteins
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
BR112015027399A2 (pt) ANTICORPOS ANTI-IGF-1R COM LIGAÇÃO DE FcRn ABOLIDA E SEU USO NO TRATAMENTO DE ENFERMIDADES VASCULARES OCULARES
IT201600101413A1 (it) Composizione liquida per uso nel trattamento del reflusso gastroesofageo
DK3307277T3 (da) Enkeltstrengede oligonukleotider til anvendelse i medicinsk behandling af hudlidelser
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
IT201600081379A1 (it) Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.
MA50358A (fr) Sémaglutide en thérapie médicale
IL269094A (en) Antibodies against eutaxin 2 for use in the treatment of liver diseases
IT201700066486A1 (it) Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche
PL3515409T3 (pl) Kompleks i kompozycje do leczenia chorób okulistycznych i dermatologicznych
PT3413870T (pt) Igmesina para utilização no tratamento de doença de alzheimer
KR20180085033A (ko) 피부 질환 치료용 약학적 제형 및 이의 제조 방법
ITUA20162781A1 (it) Kit di medicamenti per l’uso nel trattamento di lesioni dei tessuti tegumentari.